Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Stopped early · Not applicable

Conditions studied: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Recurrent Non Small Cell Lung Cancer

In brief

This trial will examine if the monitoring of daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce the rate of adverse events during the course of radiation treatment.

Key facts

Study ID

NCT04878952

Run by

NRG Oncology

People needed

3

Starts

2021-08-26

Expected to finish

2024-08-12

Last updated by the study team

2026-05-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically (histologically or cytologically) proven diagnosis of NSCLC
• Planned initiation (within the 30 days after study registration) of fractionated (≥15 treatments) thoracic radiotherapy with concurrent chemotherapy. Expected treatment scenarios include:
• Definitive treatment of stage III disease (most common)
• Definitive treatment for locoregional recurrence of early stage disease
• Definitive treatment of unresectable stage II disease
• Preoperative treatment of stage III disease
• Postoperative treatment after incomplete resection (uncommon)
• Radical treatment for a patient with advanced/metastatic disease with the goal of achieving long-term thoracic disease control (e.g., oligometastatic disease where metastases are addressed with resection or stereotactic radiotherapy)
• ECOG Performance Status 0-3 within 30 days prior to registration
• Age ≥ 18
• Ambulates independently or with a cane (use of a walker not permitted)
• Patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial. Patients must agree to wear the device provided by the study.
• The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.

You may not qualify if…

• Patients with a history of another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy for NSCLC
• Patients receiving concurrent treatment for another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy
• Patients receiving thoracic radiotherapy without concurrent chemotherapy are ineligible. Patients receiving concurrent chemotherapy and another form of systemic therapy (e.g., immunotherapy) are eligible. Patients receiving radiotherapy with concurrent immunotherapy or targeted therapy but without chemotherapy are ineligible

Where it is running

• WellSpan Health - Chambersburg — Chambersburg, Pennsylvania, United States
• WellSpan Health - Ephrata — Ephrata, Pennsylvania, United States
• WellSpan Health - Gettysburg — Gettysburg, Pennsylvania, United States
• WellSpan Health - Lebanon — Lebanon, Pennsylvania, United States
• WellSpan Health - York — York, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.